IBIO (iBio, Inc.) חוב לטווח קצר להון

The market value of iBio, Inc. (IBIO), which stands at 0.01 as illustrated on this chart, is supported by the bioplatform's independence from market volatility and strong interest in AI-driven cancer therapy. The business generates revenue through antibody development and licensing deals with industry behemoths. Simultaneously, iBio, Inc. (IBIO) is implementing sustainable production methods, minimizing harmful emissions and strictly adhering to ethical research standards.

A conservative investor assesses the stability of iBio, Inc. (IBIO) through the ratio of current liabilities to net assets, where the trend of debt under one year relative to equity reflects liquidity risk. For a company scaling its RubrYc AI platform for B2B licenses, this indicator determines the balance between aggressive market capture in immunopharmaceuticals and the ability to service short-term loans without the threat of default.